Q4 EPS Forecast for United Therapeutics Lowered by Analyst

United Therapeutics Co. (NASDAQ:UTHR - Free Report) - Equities research analysts at Leerink Partnrs decreased their Q4 2024 EPS estimates for United Therapeutics in a research note issued on Tuesday, February 11th. Leerink Partnrs analyst R. Ruiz now anticipates that the biotechnology company will earn $6.90 per share for the quarter, down from their prior forecast of $7.77. The consensus estimate for United Therapeutics' current full-year earnings is $25.21 per share. Leerink Partnrs also issued estimates for United Therapeutics' Q4 2025 earnings at $7.85 EPS.

Several other research firms also recently issued reports on UTHR. UBS Group upped their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a research note on Wednesday, January 8th. StockNews.com raised shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Thursday, January 16th. LADENBURG THALM/SH SH increased their target price on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a "buy" rating in a research note on Thursday, October 31st. TD Cowen boosted their price target on United Therapeutics from $350.00 to $400.00 and gave the company a "buy" rating in a research report on Monday, October 21st. Finally, Argus increased their price objective on United Therapeutics from $360.00 to $400.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, United Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $382.08.

United Therapeutics Stock Up 0.0 %

Shares of UTHR traded up $0.14 during trading on Thursday, reaching $370.58. 209,344 shares of the company traded hands, compared to its average volume of 312,203. The stock has a 50-day simple moving average of $361.93 and a 200-day simple moving average of $359.12. The stock has a market cap of $16.55 billion, a PE ratio of 16.27, a price-to-earnings-growth ratio of 0.92 and a beta of 0.57. United Therapeutics has a twelve month low of $211.61 and a twelve month high of $417.82.

Insider Buying and Selling

In related news, COO Michael Benkowitz sold 10,000 shares of the business's stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $372.75, for a total transaction of $3,727,500.00. Following the sale, the chief operating officer now owns 2,577 shares of the company's stock, valued at approximately $960,576.75. The trade was a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Paul A. Mahon sold 7,700 shares of the stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $374.37, for a total transaction of $2,882,649.00. Following the completion of the transaction, the executive vice president now directly owns 36,710 shares of the company's stock, valued at approximately $13,743,122.70. This trade represents a 17.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 121,864 shares of company stock valued at $44,516,965 over the last quarter. Company insiders own 11.90% of the company's stock.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Newbridge Financial Services Group Inc. purchased a new position in shares of United Therapeutics in the fourth quarter valued at $25,000. Brooklyn Investment Group purchased a new stake in shares of United Therapeutics in the 3rd quarter worth about $33,000. Dunhill Financial LLC grew its stake in United Therapeutics by 100.0% in the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 50 shares during the last quarter. Millstone Evans Group LLC purchased a new position in United Therapeutics during the 4th quarter valued at about $67,000. Finally, Capital Performance Advisors LLP acquired a new position in United Therapeutics during the third quarter worth about $82,000. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.